According to a phase 2 clinical trial by the National Institutes of Health, researchers found rare cases of severe allergic reactions to the two mRNA vaccines, mainly in people with a history of allergies and anaphylaxis, and among those with certain blood disorders. “These cases are rare, and research shows that the majority of them are mild, treatable, and triggered not by the mRNA, but other ingredients added as stabilizing agents,” said Bernadette Boden-Albala, DrPh, MPH, director and founding dean at the University of California, Irvine Program in Public Health.
With J&J vaccine restrictions, experts say we need more options beyond mRNA
Verywell Health, May 13, 2022
May 13, 2022